Preface content

Publications

There were a total of 249 results for your search.

European Commission Perspective with regards to vaccine research

Dr Jean-Claude Cavitte's Presentation on the European Commission perspective with regards to vaccine research.

Including the EU Framework programme for research and innovation: HORIZON 2020

 

Presented at the Veterinary Vaccinology Network Conference 2015

 

Can Epidemiology and economics make a meaningful contribution to national animal-disease control?

The general role of veterinary epidemiology and economics to national animal-disease control throughout the world is considered for the four main groupings of animal diseases: zoonotic, food-borne, endemic and epidemic diseases. This is done by considering how veterinary epidemiology and economics has contributed to priority setting (which diseases come first?), decision-making (for a given disease, which strategy is best?), and disease control implementation (how can optimal delivery and adoption of selected interventions best be achieved?).

IFITM3 restricts the morbidity and mortality associated with influenza

The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferon-inducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses. Both the magnitude and breadth of the IFITM proteins' in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses.

Viruses as vaccine vectors for infectious diseases and cancer

Recent developments in the use of viruses as vaccine vectors have been facilitated by a better understanding of viral biology. Advances occur as we gain greater insight into the interrelationship of viruses and the immune system. Viral-vector vaccines remain the best means to induce cellular immunity and are now showing promise for the induction of strong humoral responses.

Structural Biology and Vaccinology Presentation

Professor David Stuart's presentation on Structural Biology and Vaccinology .

Presentation from the Veterinary Vaccinology Network Conference 2015

Viruses as vaccine vectors for infectious diseases and cancer

Recent developments in the use of viruses as vaccine vectors have been facilitated by a better understanding of viral biology. Advances occur as we gain greater insight into the interrelationship of viruses and the immune system. Viral-vector vaccines remain the best means to induce cellular immunity and are now showing promise for the induction of strong humoral responses.

The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.

Adenovirus vaccine vectors generated from new viral serotypes are routinely screened in pre-clinical laboratory animal models to identify the most immunogenic and efficacious candidates for further evaluation in clinical human and veterinary settings. Here, we show that studies in a laboratory species do not necessarily predict the hierarchy of vector performance in other mammals.

Veterinary Vaccine R&D - A commercial perspective

Brief synopsis of a presentation given at the First UK Veterinary Vaccinology Forum Confreence, ICC, Birmingham on the 16th Feb 2015

A Novel Murine Cytomegalovirus Vaccine Vector Protects against Mycobacterium tuberculosis

Tuberculosis remains a global health problem so that a more effective vaccine than bacillus Calmette-Guérin is urgently needed. Cytomegaloviruses persist lifelong in vivo and induce powerful immune and increasing ("inflationary") responses, making them attractive vaccine vectors. We have used an m1-m16-deleted recombinant murine CMV (MCMV) expressing Mycobacterium tuberculosis Ag 85A to show that infection of mice with this recombinant significantly reduces the mycobacterial load after challenge with M. tuberculosis, whereas control empty virus has a lesser effect.

Pages

Call to action content

Newsletter

Trim content

Copyright: The Pirbright Institute 2014-2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.